Aktieanalys

Active Biotech Q1 2023: New Results from naptumomab - Redeye

{newsItem.title}

Redeye Publicerad: 04 May 2023 11:52

Redeye comments on Active Biotech’s Q1 report. After the end of Q1, results from naptumomab’s phase I/IIa study with durvalumab were published which we discuss.

Länk till analysen i sin helhet: https://www.redeye.se/research/902281/active-biotech-q1-2023-new-results-from-naptumomab?utm_source=finwire&utm_medium=RSS

Nyheter om Active Biotech

Läses av andra just nu

Om aktien Active Biotech

Senaste nytt